Healthcare & Life Sciences

Scientific Literature Reference Copyright Restricted

FDA published a document on regulations.gov (FDA-2026-P-3869-0004) regarding scientific literature references. The submission contains copyright-restricted content and is not fully accessible to the public. The document appears to be a regulatory submission or comment filed with FDA.

FDA Complaint FDA-2026-H-3943-0001

FDA received a complaint under docket FDA-2026-H-3943-0001 on April 15, 2025. The Center for Tobacco Products authored the complaint. The public comment period for this docket is now closed. No documents are available for viewing or download from the regulatory docket.

Scientific Reference Costenbader 2007, FDA-2026-P-3869

FDA has published a scientific reference document (Costenbader 2007) as part of docket FDA-2026-P-3869. The document was submitted as supporting scientific literature for a Pre-Market Notification submission. The actual content is restricted due to copyright and cannot be displayed.

Yang 2022 Scientific Literature Reference

A scientific literature reference authored by Yang (2022) was submitted to FDA docket FDA-2026-P-3869 as supporting documentation. The document was filed on April 3, 2025, and is accessible via regulations.gov. This appears to be part of a food additive petition or similar regulatory submission process requiring scientific literature support.

Scientific Literature Reference Rao 2017 FDA-2026-P-3869

A scientific literature reference (Rao 2017) has been submitted to FDA docket FDA-2026-P-3869. The document appears to be supporting scientific literature provided as part of comments or a submission to the FDA regulatory process. No regulatory requirements, deadlines, or penalties are established by this document submission.

Sanchez-Guerrero 1997 Scientific Literature Reference

FDA has received and filed a scientific literature reference (Sanchez-Guerrero 1997) in regulatory docket FDA-2026-P-3869. The document has been uploaded to the public docket and is accessible to interested parties. The content of the reference cannot be displayed due to copyright restrictions.

Scientific Literature Reference - Content Restricted

FDA received a submission on regulations.gov containing a scientific literature reference that is restricted due to copyright limitations. The specific content of the referenced literature is not accessible. The submission appears in FDA's docket system but the substantive regulatory material cannot be reviewed.

Citizen Petition to FDA by Kaylin Bower

A citizen petition was filed with the FDA's Center for Drug Evaluation and Research (CDER) by Kaylin Bower on April 15, 2026. The petition docket is FDA-2026-P-4104-0001. The full contents of the petition are redacted due to personally identifiable information protections, limiting visibility into the specific regulatory relief requested.

Manhart 2013 Scientific Literature Submission FDA-2026-P-3869

FDA has received a docket submission to FDA-2026-P-3869 containing a citation to Manhart 2013 scientific literature. The full content of the submission is restricted due to copyright and is not publicly viewable in the docket.

Narula 2022 IBD Scientific Literature, FDA-2026-P-3869

Narula 2022 IBD Scientific Literature, FDA-2026-P-3869

Measles Case Identified in Weld County Resident

The Colorado Department of Public Health and Environment and Weld County Public Health have identified a measles case in an unvaccinated adult Weld County resident who is a close contact of previous cases. Potential exposure locations have been identified at two healthcare facilities in Larimer County. Public health officials are advising anyone who visited the listed locations at the specified times to monitor for symptoms for 21 days.

Texas Home Health Providers - HHSC-OIG Common Billing Errors and $95.7M Recovered

The Texas Health and Human Services Office of Inspector General (HHSC-OIG) recovered more than $95.7 million from December 1, 2025, to February 28, 2026. Home health agencies ranked first among provider types in preliminary investigations at 21 percent of cases and third in full-scale investigations at 15 percent. Common billing errors identified include failure to perform required nursing assessments, documentation deficiencies, and billing irregularities such as billing for services when clients were at inpatient facilities or misrepresenting nurse credentials.

Healthcare Incentive Decisions Resurface in Audits and Diligence

This article examines how healthcare incentive compensation decisions resurface during audits, partner disputes, payer challenges, and transaction due diligence. It identifies documentation patterns that create risk for healthcare organizations, including discretionary payments without adequate records, one-off compensation adjustments that become permanent without review, and inconsistent explanations for incentive payments. The article advises that when documentation is thin or inconsistent, reviewers fill gaps with risk assumptions.

A&O Shearman Releases Second Life Sciences and Healthcare Insights Report

A&O Shearman has released the second edition of its Life Sciences and Healthcare Insights report. The publication covers six topics including shareholder activism trends, AI use in drug discovery, China's emergence as a pharma innovation hub, proposed EU MDR and IVDR reforms, the UPC's impact on European patent litigation, and EU environmental sustainability requirements for pharmaceutical companies. The report is informational and does not create compliance obligations.

FDA Public Meeting on Dietary Supplement Ingredients

FDA's Office of Dietary Supplement Programs held a public meeting on March 27, 2026, to discuss the evolving landscape of dietary supplement ingredients and how scientific and technological advances are shaping the industry. The meeting covered three sessions: the scope of 'dietary supplements' under DSHEA, emerging production technologies, and identification of proteins, enzymes, and microbials. FDA posed three feedback questions to stakeholders regarding novel ingredient types, production methodology changes, and characterization requirements.

Recent Court Decisions Favor Employers in Tobacco Surcharge Litigation

Warner Norcross + Judd summarizes three recent federal district court decisions (Plesha v. Ascension Health Alliance, E.D. Mo.; Greene v. Progressive Corp., N.D. Ohio; Noel v. PepsiCo, Inc., S.D.N.Y.) dismissing ERISA class action claims challenging employer tobacco surcharge wellness programs. Courts held that employers need not provide retroactive refunds of tobacco surcharges, that disclosure language substantially similar to DOL model notice satisfies requirements, and that tobacco surcharge design is a settlor function rather than a fiduciary duty. The analysis signals a trend generally favorable to employers while noting dozens of similar lawsuits remain pending nationwide.

Healthcare Providers Warned About Medical Tech Contract AI, Evergreen Risks

Buchalter published an advisory warning healthcare providers about two emerging contract risks: (1) evergreen renewal provisions that automatically extend agreements without opportunity to renegotiate AI-related terms, and (2) expansive vendor data rights that may permit use of provider data for AI model training and product development without clear disclosure. The advisory identifies risks including re-identification of de-identified data, vendor IP accrual from provider operations, and unclear liability for AI-generated clinical or billing outputs.

California Senior Living–2026 Legal, Regulatory, and Insurance Update Webinar

Hinshaw & Culbertson LLP announces a webinar on April 29, 2026 for California senior living providers covering insurance market changes, claims trends affecting nursing homes and RCFEs, and legal developments influencing liability exposure. The webinar offers 1.0 hours of NAB and RCFE continuing education credits. This is an educational announcement with no regulatory changes or compliance mandates.

State Health Planning Board Confirms Public Hearing for Hospital Closure Certificate of Need Application

The New Jersey Department of Health's State Health Planning Board has scheduled a public hearing for April 15, 2026, to accept public comments on a Certificate of Need application for the closure of Heights University Hospital in Jersey City. The hospital application and related materials are available at the Jersey City Public Library, New Jersey State Library, and the NJDOH website. Written comments may also be submitted until April 22, 2026, via email or mail.

Roche Oligonucleotides for Paternal UBE3A Expression

The European Patent Office published patent application EP3798307A1 for F. Hoffmann-La Roche AG covering oligonucleotides designed to induce paternal UBE3A expression. The invention relates to nucleic acid therapeutics targeting UBE3A gene expression, with applications in treating genetic disorders. The patent application was filed under IPC classification C12N 15/113 and designates all 39 contracting states across the European Patent Convention.

FDA Clarifies GLP-1 Compounding Policy for Pharmacy Compounders

FDA Clarifies GLP-1 Compounding Policy for Pharmacy Compounders

Federal Court Vacates HRSA 340B GPO Prohibition Replenishment Model Policy

The US District Court for the District of Columbia vacated HRSA's 2013 policy prohibiting 340B covered entities from using group purchasing organizations with replenishment (virtual inventory) models. The court granted Premier's motion for summary judgment, finding HRSA's policy arbitrary and capricious under the Administrative Procedure Act due to inadequate reasoned explanation. The court denied defendants' cross-motion for summary judgment.

CAA 2026 Medicare Part D Pharmacy Provisions Primer

H.R.7148, the Consolidated Appropriations Act, 2026, became law on February 3, 2025, introducing new pharmacy-related requirements under Sections 6223 and 6224 focused on Medicare Part D. Section 6223 expands 'Any Willing Pharmacy' contracting requirements and creates new affiliate and non-affiliate pharmacy designations, while Section 6224 limits PBM compensation to bona fide service fees and requires passthrough of manufacturer rebates and discounts to PDP sponsors.

HIPAA PHI Disposal Requirements, Methods, and Training

Shumaker, Loop & Kendrick published a client alert summarizing HHS guidance on HIPAA Privacy and Security Rule requirements for disposing of protected health information. The alert explains that covered entities must implement reasonable safeguards, policies, and procedures for PHI disposal in any form, and must train workforce members on disposal practices. The article references 45 CFR 164.530(c) and 45 CFR 164.310(d)(2)(i) and (ii).

Georgia SB 220 THC Cap, 12,000mg Limit, SB 33 Hemp

Two Georgia Senate bills await Governor Brian Kemp's decision by mid-May 2026. Senate Bill 220 would eliminate Georgia's 5% THC concentration cap and replace it with a 12,000-milligram patient possession limit, while rebranding 'Low THC Oil' to 'Medical Cannabis' throughout state code. Senate Bill 33 would ban synthetic hemp products like HHC by 2027 while preserving delta-8 THC products on the market.

Life Sciences and Healthcare Insights (UPDATED)

A&O Shearman published its Life Sciences and Healthcare Insights report, offering a global compilation of legal and regulatory updates from the firm's international team. The report addresses commercial, legal, and regulatory issues affecting life sciences and healthcare companies worldwide. Topics covered include environmental sustainability, regulatory frameworks, and emerging compliance considerations across jurisdictions.

Percussionaire Corp Issues Phasitron 5 In-Line Valve Correction, Updates Use Instructions

Percussionaire Corporation issued an Urgent Medical Device Correction for the Phasitron 5 In-Line Valve (P5-TEE) due to a design limitation where leaks can occur through the pressure relief valve even when fully closed. The FDA classified this as a Class I recall, the most serious type. Leakage poses a high risk of cardiopulmonary and neurological compromise in neonatal and infant patients due to unrecognized hypoventilation, potentially causing respiratory acidosis, hypoxemia, or respiratory failure. Four serious injuries have been reported as of September 3, 2025, with no deaths.

Raglan 2019 Supporting Material

FDA received supporting material dated April 15, 2019, associated with submission FDA-2026-P-3869. The document content is restricted due to copyright. No specific regulatory requirements, deadlines, or penalties are stated in the visible portion of the document.

Peragallo 2018 Supporting Material FDA-2026-P-3869

FDA received supporting materials for Citizen Petition FDA-2026-P-3869 submitted by Peragallo. The document consists of 2018 supporting material referenced in the petition but the content is restricted due to copyright. The petition and supporting documentation were filed in the public docket for regulatory review.

Klaus 1982 FDA Document

FDA received a document submission dated April 15, 1982, from Klaus. The document content is restricted due to copyright and is not publicly accessible through regulations.gov. The submission is catalogued under docket FDA-2026-P-3869-0005. Specific regulatory content cannot be determined from the available metadata.

Hellwig 2016 Background Material - FDA Docket FDA-2026-P-3869

FDA received background material originally prepared in 2016 and filed in docket FDA-2026-P-3869. The document appears to be supporting documentation associated with an FDA petition. No new regulatory requirements or compliance obligations are established by this filing.

Persson 1993 Background Material Submission FDA Docket

FDA has received and placed in docket FDA-2026-P-3869 background material titled 'Persson 1993' for public access. The document contains copyrighted content that is restricted from public viewing. This appears to be historical scientific literature submitted as supporting material in an FDA regulatory proceeding. No new regulatory requirements, deadlines, or compliance obligations are established by this docket filing.

Larsen 2008 FDA Document

This document (FDA-2026-P-3869-0117) appears in the FDA section of Regulations.gov. The full content is not accessible as it has been restricted due to copyright protections. No substantive regulatory requirements, deadlines, or obligations can be determined from the available metadata.

Persson 1993 Background Material, FDA-2026-P-3869

FDA has posted background material submitted by Persson in docket FDA-2026-P-3869. The document, dated 1993, has been added to the public docket. The content is restricted due to copyright. No specific regulatory requirements or deadlines are stated in the available metadata.

Piovani 2019 Supplemental Tables Supporting FDA Petition

FDA received supplemental tables (Piovani 2019) as supporting material filed under docket FDA-2026-P-3869. The document contains scientific data tables submitted to support a petition or submission before the agency. Affected parties should monitor this docket for related FDA actions or correspondence.

Konkle 2012 Background Material - FDA-2026-P-3869

FDA has received and posted background material (Konkle 2012) as part of docket FDA-2026-P-3869. The document content is restricted due to copyright and is not publicly accessible. The filing represents supporting documentation submitted to the FDA docket for regulatory review.

Ghajarzadeh 2022 Background Material for FDA Petition

FDA received background material from Ghajarzadeh dated 2022 as part of petition FDA-2026-P-3869. The submission consists of supporting documentation for a petition requesting FDA to take a specific regulatory action. The document was filed in the FDA regulations.gov docket system. No specific petition request, compliance obligations, or deadlines are stated in the available metadata.

Chen 2017 Background Material, FDA-2026-P-3869, Apr 3

Chen 2017 Background Material, FDA-2026-P-3869, Apr 3

FDA READI-Home Innovation Challenge for Medical Device Technologies

The FDA's Center for Devices and Radiological Health (CDRH) launched the Reducing Readmissions through Device Innovation for the Home (READI-Home) Innovation Challenge on April 7, 2026. The challenge invites medical device innovators to develop home-based technologies that support patients and caregivers following acute hospital stays and help prevent readmissions. Submissions must meet the FD&C Act device definition and address unmet home healthcare needs.

CDC Agency Forms Undergo Paperwork Reduction Act Review

CDC published a notice announcing that certain agency forms are undergoing the Paperwork Reduction Act review process. The notice identifies forms under review by docket number 30Day-26-1335 and invites public comment on these information collections. Affected parties who submit information to CDC using these forms may wish to monitor the review for any changes to reporting requirements.

CDC Proposes Data Collection Under Paperwork Reduction Act

The CDC has published a notice proposing a new data collection under the Paperwork Reduction Act. The notice requests public comments on the proposed collection of information. The comment period closes 61 days from the date of publication.

CDC Proposes Data Collection Under Paperwork Reduction Act

CDC proposes a new data collection under the Paperwork Reduction Act and seeks public comments. The notice requests feedback on the proposed data collection, associated burden estimates, and collection methods. Comments are due June 15, 2026.

Call for Nominations for Center for Indigenous Innovation and Health Tribal Advisory Committee

The HHS Office on Minority Health (OMH) is accepting nominations for primary and alternate delegates to serve on the Center for Indigenous Innovation and Health Tribal Advisory Committee (CIIH TAC). The CIIH TAC provides tribal leaders a forum to exchange views and provide feedback on activities addressing four priority areas: research, education, service, and policy development. Nomination letters must be submitted by May 18, 2026.

Advisory Council on Alzheimer's Research, Care, and Services Meeting

HHS announces a public meeting of the Advisory Council on Alzheimer's Research, Care, and Services scheduled for Monday, April 27, 2026, from 1:00 p.m. to 5:00 p.m. The meeting is open to the public for attendance and comment participation. This is a routine advisory council meeting announcement with no new compliance obligations.

CMS Schedules June 2026 Public Meeting on HCPCS Level II Code Revisions

CMS announces the first biannual 2026 public meeting for HCPCS Level II coding to discuss preliminary coding, Medicare benefit category, and payment determinations for new non-drug and non-biological items and services. The primary meeting is scheduled for June 1, 2026, in Baltimore with a virtual overflow option on June 2, 2026. Speaker registration and in-person attendance requests are due by May 18, 2026, and written comments may be submitted until June 3, 2026.

FDA Oversight of Compounded GLP-1 Drugs, Active

HHS OIG announced an active study to assess FDA's oversight of compounded glucagon-like peptide-1 receptor agonist (GLP-1) drugs. The study will examine FDA's inspection of compounding facilities and use of available data to identify and address potential risks to patients. GLP-1 drugs were on FDA's drug shortage list from 2022 to 2025, during which compounding facilities were permitted to produce copies. The study is estimated for completion in fiscal year 2028.

NIH Recipients' Oversight of Domestic Subrecipients

HHS OIG announced a new evaluation (OEI-04-26-00170) to assess NIH prime recipients' adherence to requirements for oversight of domestic subrecipients under the NIH Grants Policy Statement and OMB Uniform Guidance. The evaluation aims to reduce fraud, waste, and abuse in domestic NIH subawards, with an estimated completion date of FY2028.

TANF Cash Assistance Program Oversight Audit Series Announced

HHS OIG announced a new audit series (SRS-A-26-017) to examine state oversight of the Temporary Assistance for Needy Families (TANF) program, which distributes $16.6 billion annually in federal block grant funds to states. The audits will focus on whether states provided adequate oversight of TANF cash assistance programs, including the use of electronic benefit transfer (EBT) cards. One project (OAS-26-09-021) has been announced with an estimated completion in FY2028.

IDOH Vital Records LHD Webinar

The Indiana Department of Health has scheduled a virtual webinar on vital records for Local Health Department staff on April 16, 2026 from 10:00am to 11:00am EDT. The event is hosted by IDOH's LHD Program and appears to be an informational training session. No regulatory requirements, compliance obligations, or new policies are being established through this event.

Delaware Healthy Mother & Infant Consortium Celebrates 20th Anniversary During Annual Summit

The Delaware Healthy Mother & Infant Consortium marked its 20th anniversary at its annual summit with a keynote address by Multi-Emmy Award-winning director Emmai Alaquiva. Alaquiva discussed his award-winning film The Ebony Canal and addressed maternal health disparities affecting Black and Brown communities. The event celebrated the consortium's two decades of work on infant outcomes in Delaware.